Boston Scientific (BSX)
(Delayed Data from NYSE)
$77.11 USD
+0.99 (1.30%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $77.10 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Brokerage Reports
Boston Scientific Corporation [BSX]
Reports for Purchase
Showing records 481 - 500 ( 512 total )
Company: Boston Scientific Corporation
Industry: Medical - Products
Company: Boston Scientific Corporation
Industry: Medical - Products
Company: Boston Scientific Corporation
Industry: Medical - Products
Company: Boston Scientific Corporation
Industry: Medical - Products
Back Away From the Table - Another Tough Year in 2011 - Only Modest Improvement Likely in 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Boston Scientific Corporation
Industry: Medical - Products
Q4 Sales On Track, EPS Better -- But Q1 and Full 2011 Guidance Comes Up Short
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Boston Scientific Corporation
Industry: Medical - Products
Company: Boston Scientific Corporation
Industry: Medical - Products
M&A Pattern Continues With 4th Early-Stage Acquisition in Four Months ? No Fix for Low-Growth
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Boston Scientific Corporation
Industry: Medical - Products
Scores Big in Whopping $1.5 Billion Target Unit Sale to SYK - Some Help for the Balance Sheet and Acquisition Fund
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Boston Scientific Corporation
Industry: Medical - Products
Company: Boston Scientific Corporation
Industry: Medical - Products
Company: Boston Scientific Corporation
Industry: Medical - Products
Q3 Sales Weak as Expected -EPS Beats With a Lot of Help from the Tax Man.
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Boston Scientific Corporation
Industry: Medical - Products
Med Tech September Quarter Preview: Stagnation for Most Large Device Markets
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Boston Scientific Corporation
Industry: Medical - Products
Company: Boston Scientific Corporation
Industry: Medical - Products
Unclear How BSX Will Use Asset Sale Proceeds, So Hard To Say How Deal(s) Will Affect Debt Levels & Income Statement No Relief In Sight For Tough Operating Environment
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Boston Scientific Corporation
Industry: Medical - Products
Company: Boston Scientific Corporation
Industry: Medical - Products
Company: Boston Scientific Corporation
Industry: Medical - Products
Company: Boston Scientific Corporation
Industry: Medical - Products
Q2 Results Titillate -- A Strong ICD Rebound after the Recall But Business Trends Remain Weak, and the Outlook Leaves Us Unfulfilled.
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Boston Scientific Corporation
Industry: Medical - Products
Medical Technology -Med Tech June Quarter Preview: Nothing on the Horizon to Lift the Sector Out of the Doldrums, Although Select Small-Cap Names Should Shine Through
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P